WO2012078540A1 - Modulation de l'activité des cellules immunitaires au moyen de l'homologie src induite par les cytokines 2 et/ou nécessitant des températures élevées a-1 - Google Patents

Modulation de l'activité des cellules immunitaires au moyen de l'homologie src induite par les cytokines 2 et/ou nécessitant des températures élevées a-1 Download PDF

Info

Publication number
WO2012078540A1
WO2012078540A1 PCT/US2011/063375 US2011063375W WO2012078540A1 WO 2012078540 A1 WO2012078540 A1 WO 2012078540A1 US 2011063375 W US2011063375 W US 2011063375W WO 2012078540 A1 WO2012078540 A1 WO 2012078540A1
Authority
WO
WIPO (PCT)
Prior art keywords
htral
cish
seq
nucleotide sequence
cells
Prior art date
Application number
PCT/US2011/063375
Other languages
English (en)
Inventor
Douglas C. Palmer
Nicholas P. Restifo
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2012078540A1 publication Critical patent/WO2012078540A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C12N2501/734—Proteases (EC 3.4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention a pour objet une cellule de sang périphérique (PBC) comprenant un activateur de la sérine peptidase nécessitant des températures élevées 1 (HTRA1)/htra1, une cellule hôte comprenant un inhibiteur de la protéine d'homologie Src induite par les cytokines 2 (CIS)/cish et un activateur de HTRA1/htra1, une cellule hôte comprenant un shMIR anti-cish comprenant SEQ ID NO : 3 ou 4, et des populations de cellules associées, des compositions pharmaceutiques, des méthodes de traitement ou de prévention du cancer ou d'une maladie infectieuse chronique chez un mammifère, et des méthodes d'augmentation de l'activité des lymphocytes T chez un mammifère. La présente invention concerne également une cellule hôte comprenant un inhibiteur de HTRA1/htra1 et un activateur de CIS/cish, une PBC comprenant un inhibiteur de HTRA1/htra1, et des populations de cellules associées, des compositions pharmaceutiques, des méthodes de traitement ou de prévention d'une maladie auto- et/ou allo-immune chez un mammifère, et des méthodes de suppression de l'activité des lymphocytes T chez un mammifère.
PCT/US2011/063375 2010-12-08 2011-12-06 Modulation de l'activité des cellules immunitaires au moyen de l'homologie src induite par les cytokines 2 et/ou nécessitant des températures élevées a-1 WO2012078540A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42082510P 2010-12-08 2010-12-08
US61/420,825 2010-12-08

Publications (1)

Publication Number Publication Date
WO2012078540A1 true WO2012078540A1 (fr) 2012-06-14

Family

ID=45390194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/063375 WO2012078540A1 (fr) 2010-12-08 2011-12-06 Modulation de l'activité des cellules immunitaires au moyen de l'homologie src induite par les cytokines 2 et/ou nécessitant des températures élevées a-1

Country Status (1)

Country Link
WO (1) WO2012078540A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016502546A (ja) * 2012-12-03 2016-01-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換トリアゾールボロン酸化合物
WO2016100555A1 (fr) * 2014-12-18 2016-06-23 Inception 4, Inc. Dérivés d'acide boronique et leurs utilisations
WO2017100861A1 (fr) * 2015-12-16 2017-06-22 The Walter And Eliza Hall Institute Of Medical Research Inhibition de protéines sh2 induites par des cytokines dans des cellules nk
WO2017222915A1 (fr) 2016-06-21 2017-12-28 Inception 4, Inc. Dérivés hétérocycliques de prolinamide
WO2017222914A1 (fr) 2016-06-21 2017-12-28 Inception 4, Inc. Dérivés de prolinamide carbocycliques
US10166255B2 (en) * 2015-07-31 2019-01-01 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
US20190008899A1 (en) * 2016-10-18 2019-01-10 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
JP2019525952A (ja) * 2016-06-21 2019-09-12 オリオン・オフサルモロジー・エルエルシー 脂肪族プロリンアミド誘導体
US11098325B2 (en) 2017-06-30 2021-08-24 Intima Bioscience, Inc. Adeno-associated viral vectors for gene therapy
AU2017347854B2 (en) * 2016-10-27 2022-12-08 Intima Bioscience, Inc. Viral methods of T cell therapy

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026807A1 (fr) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Agents pour le traitement ou la prevention d'une affection allergique
WO2009006460A1 (fr) * 2007-07-02 2009-01-08 Alcon Research, Ltd. Inhibition véhiculée par arni de htra1 pour le traitement de la dégénérescence maculaire
US20090053184A1 (en) 2004-09-13 2009-02-26 Government Of The United States Of America, Repres Ented By The Secretary, Department Of Health Compositions comprising t cell receptors and methods of use thereof
WO2009042570A2 (fr) 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs de lymphocytes t modifiés et matériaux et procédés associés
WO2010068413A1 (fr) * 2008-11-25 2010-06-17 Emergent Product Development Gaithersburg Inc. Vaccin anti-chlamydia comprenant des polypeptides htra
WO2010088160A1 (fr) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs des lymphocytes t, matières correspondantes et procédés d'utilisation
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026807A1 (fr) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Agents pour le traitement ou la prevention d'une affection allergique
US20090053184A1 (en) 2004-09-13 2009-02-26 Government Of The United States Of America, Repres Ented By The Secretary, Department Of Health Compositions comprising t cell receptors and methods of use thereof
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2009006460A1 (fr) * 2007-07-02 2009-01-08 Alcon Research, Ltd. Inhibition véhiculée par arni de htra1 pour le traitement de la dégénérescence maculaire
WO2009042570A2 (fr) 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs de lymphocytes t modifiés et matériaux et procédés associés
WO2010068413A1 (fr) * 2008-11-25 2010-06-17 Emergent Product Development Gaithersburg Inc. Vaccin anti-chlamydia comprenant des polypeptides htra
WO2010088160A1 (fr) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs des lymphocytes t, matières correspondantes et procédés d'utilisation

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
"Current Protocols In Molecular Biology", 1994, CURRENT PROTOCOLS PRESS
"Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
AAGAARD ET AL., MOL. THER., vol. 15, no. 5, 2007, pages 938 - 45
ABAD ET AL., J. IMMUNOTHER., vol. 31, 2008, pages 1 - 6
ALTSCHUL ET AL., J MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
AMAN ET AL., J BIOL. CHEM., vol. 274, 1999, pages 30266 - 72
AMAN ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 30266 - 72
BALDI ALFONSO ET AL: "THE HTRA1 SERINE PROTEASE IS DOWN-REGULATED DURING HUMAN MELANOMA PROGRESSION AND REPRESSES GROWTH OF METASTATIC MELANOMA CELLS", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 21, no. 43, 1 January 2002 (2002-01-01), pages 6684 - 6688, XP002976435, ISSN: 0950-9232, DOI: 10.1038/SJ.ONC.1205911 *
BANKER AND CHALMERS: "Pharmaceutics and Pharmacy Practice", 1982, J.B. LIPPINCOTT COMPANY, pages: 238 - 250
BERGER; KIMMEL: "Methods In Enzymology: Guide To Molecular Cloning Techniques", vol. 152, 1987, ACADEMIC PRESS, INC.
CHEN SHANGWU ET AL: "Functional association of cytokine-induced SH2 protein and protein kinase C in activated T cells.", INTERNATIONAL IMMUNOLOGY, vol. 15, no. 3, March 2003 (2003-03-01), pages 403 - 409, XP009158620, ISSN: 0953-8178 *
EL-ASADY ET AL., J. EXP. MED., vol. 201, 2005, pages 1647 - 57
ENGELS ET AL., ANGEW. CHEM. INTL. ED., vol. 28, 1989, pages 716 - 734
GELLIBERT ET AL., J. MED. CHEM., vol. 47, 2004, pages 4494 - 506
HEEMSKERK ET AL., HUM. GENE THER., vol. 19, no. 5, 2008, pages 496 - 510
JOHNSON ET AL., BLOOD, vol. 114, no. 3, 2009, pages 535 - 46
KARLIN; ALTSCHUL ET AL., PROC. NAT. ACAD SCI. USA, vol. 90, 1993, pages 5873 - 5877
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 2002, pages 2264 - 2268
KHOR CHIEA C ET AL: "CISH and Susceptibility to Infectious Diseases", NEW ENGLAND JOURNAL OF MEDICINE, vol. 362, no. 22, June 2010 (2010-06-01), pages 2092 - 2101, XP009158597 *
LAUNAY ET AL., CELL DEATH DIFFER., vol. 15, 2008, pages 1408 - 16
LI ET AL., CELL, vol. 134, 2008, pages 392 - 04
LIN ET AL., J. IMMUNOL., vol. 175, 2005, pages 547 - 54
MATSUMOTO ET AL., BLOOD, vol. 89, 1997, pages 3148 - 54
PALMER ET AL., PNAS, vol. 105, 2008, pages 8061 - 66
PALMER ET AL., PNAS, vol. 105, no. 23, 2008, pages 8061 - 66
SANJABI ET AL., IMMUNITY, vol. 31, 2009, pages 131 - 44
TINOCO ET AL., IMMUNITY, vol. 31, 2009, pages 145 - 57
TOCHARUS ET AL., DEV. GROWTH DIFFER., vol. 46, 2004, pages 257 - 74
TOISSEL: "ASHP Handbook on Injectable Drugs, 4th ed.,", 1986, pages: 622 - 630
TSUCHIYA ET AL., BONE, vol. 37, 2005, pages 323 - 36
USS ET AL., J. IMMUNOL., vol. 177, 2006, pages 2775 - 83
WAN ET AL., IMMUNOL. REV., vol. 220, 2007, pages 199 - 13
WAN ET AL., J CLIN. IMMUNOL., vol. 2, 2008, pages 647 - 59
XU ET AL., PNAS, vol. 94, 1997, pages 12473 - 78
YOSHIMURA ET AL., EMBO J., vol. 14, 1995, pages 2816 - 26
ZURAWA-JANICKA DOROTA ET AL: "HtrA proteins as targets in therapy of cancer and other diseases", EXPERT OPINION ON THERAPEUTIC TARGETS, ASHLEY PUBLICATIONS, LONDON, GB, vol. 14, no. 7, 1 January 2010 (2010-01-01), pages 665 - 679, XP008124102, ISSN: 1472-8222, DOI: 10.1517/14728222.2010.487867 *

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464098B2 (en) 2012-12-03 2016-10-11 Hoffmann-La Roche Inc. Substituted triazole boronic acid compounds
JP2016502546A (ja) * 2012-12-03 2016-01-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換トリアゾールボロン酸化合物
WO2016100555A1 (fr) * 2014-12-18 2016-06-23 Inception 4, Inc. Dérivés d'acide boronique et leurs utilisations
US11642374B2 (en) 2015-07-31 2023-05-09 Intima Bioscience, Inc. Intracellular genomic transplant and methods of therapy
US11147837B2 (en) 2015-07-31 2021-10-19 Regents Of The University Of Minnesota Modified cells and methods of therapy
US11925664B2 (en) 2015-07-31 2024-03-12 Intima Bioscience, Inc. Intracellular genomic transplant and methods of therapy
US11903966B2 (en) * 2015-07-31 2024-02-20 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
US11266692B2 (en) 2015-07-31 2022-03-08 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
US10166255B2 (en) * 2015-07-31 2019-01-01 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
US11583556B2 (en) 2015-07-31 2023-02-21 Regents Of The University Of Minnesota Modified cells and methods of therapy
US11642375B2 (en) 2015-07-31 2023-05-09 Intima Bioscience, Inc. Intracellular genomic transplant and methods of therapy
US10406177B2 (en) 2015-07-31 2019-09-10 Regents Of The University Of Minnesota Modified cells and methods of therapy
US20180298101A1 (en) * 2015-12-16 2018-10-18 The Walter And Eliza Hall Institute Of Medical Research Inhibition of Cytokine-Induced SH2 Protein in NK Cells
EP3827838A1 (fr) * 2015-12-16 2021-06-02 The Walter and Eliza Hall Institute of Medical Research Inhibition de protéines sh2 induites par des cytokines dans des cellules nk
EP4253412A3 (fr) * 2015-12-16 2023-11-22 The Walter and Eliza Hall Institute of Medical Research Inhibition de protéines sh2 induites par des cytokines dans des cellules nk
EP3389695A4 (fr) * 2015-12-16 2019-10-09 The Walter and Eliza Hall Institute of Medical Research Inhibition de protéines sh2 induites par des cytokines dans des cellules nk
US11492404B2 (en) 2015-12-16 2022-11-08 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
US11339220B2 (en) 2015-12-16 2022-05-24 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
US10975149B2 (en) 2015-12-16 2021-04-13 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
JP2019505498A (ja) * 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
AU2020294337C1 (en) * 2015-12-16 2022-04-21 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
US11104735B2 (en) 2015-12-16 2021-08-31 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
WO2017100861A1 (fr) * 2015-12-16 2017-06-22 The Walter And Eliza Hall Institute Of Medical Research Inhibition de protéines sh2 induites par des cytokines dans des cellules nk
US11279760B2 (en) 2015-12-16 2022-03-22 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
AU2020294337B2 (en) * 2015-12-16 2021-11-04 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
AU2016374497B2 (en) * 2015-12-16 2022-03-10 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
CN109476637A (zh) * 2016-06-21 2019-03-15 奥瑞恩眼科有限责任公司 杂环脯氨酰胺衍生物
KR102595723B1 (ko) 2016-06-21 2023-10-27 오리온 옵탈몰로지 엘엘씨 헤테로시클릭 프롤린아미드 유도체
CN109476637B (zh) * 2016-06-21 2022-02-01 奥瑞恩眼科有限责任公司 杂环脯氨酰胺衍生物
WO2017222915A1 (fr) 2016-06-21 2017-12-28 Inception 4, Inc. Dérivés hétérocycliques de prolinamide
WO2017222914A1 (fr) 2016-06-21 2017-12-28 Inception 4, Inc. Dérivés de prolinamide carbocycliques
US11866422B2 (en) 2016-06-21 2024-01-09 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
JP7076438B2 (ja) 2016-06-21 2022-05-27 オリオン・オフサルモロジー・エルエルシー 脂肪族プロリンアミド誘導体
CN114685453A (zh) * 2016-06-21 2022-07-01 奥瑞恩眼科有限责任公司 杂环脯氨酰胺衍生物
US11377439B2 (en) 2016-06-21 2022-07-05 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
JP7179721B2 (ja) 2016-06-21 2022-11-29 オリオン・オフサルモロジー・エルエルシー 複素環式プロリンアミド誘導体
US11267803B2 (en) 2016-06-21 2022-03-08 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
JP2019525952A (ja) * 2016-06-21 2019-09-12 オリオン・オフサルモロジー・エルエルシー 脂肪族プロリンアミド誘導体
JP2019519611A (ja) * 2016-06-21 2019-07-11 オリオン・オフサルモロジー・エルエルシー 複素環式プロリンアミド誘導体
KR20190011322A (ko) * 2016-06-21 2019-02-01 오리온 옵탈몰로지 엘엘씨 헤테로시클릭 프롤린아미드 유도체
EP4257191A2 (fr) 2016-06-21 2023-10-11 Orion Ophthalmology LLC Dérivés hétérocycliques de prolinamide
US20190008899A1 (en) * 2016-10-18 2019-01-10 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
US10912797B2 (en) 2016-10-18 2021-02-09 Intima Bioscience, Inc. Tumor infiltrating lymphocytes and methods of therapy
US11154574B2 (en) 2016-10-18 2021-10-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
AU2017347854B2 (en) * 2016-10-27 2022-12-08 Intima Bioscience, Inc. Viral methods of T cell therapy
US11098325B2 (en) 2017-06-30 2021-08-24 Intima Bioscience, Inc. Adeno-associated viral vectors for gene therapy

Similar Documents

Publication Publication Date Title
US11464806B2 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
WO2012078540A1 (fr) Modulation de l'activité des cellules immunitaires au moyen de l'homologie src induite par les cytokines 2 et/ou nécessitant des températures élevées a-1
JP7223055B2 (ja) 癌治療のための併用免疫療法及びサイトカイン制御療法
US20230084027A1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
Winer et al. IL-7: Comprehensive review
Nicolini et al. Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology
WO2019124468A1 (fr) Cellule immunocompétente exprimant une molécule de surface cellulaire reconnaissant spécifiquement la mésothéline humaine, il-7 et ccl19
US20220381772A1 (en) Systems and methods for evaluating nk cells
WO2017079113A1 (fr) Procédés de production de populations de lymphocytes t à l'aide d'inhibiteurs de protéines contenant un domaine prolyl hydroxylase
US10071134B2 (en) Therapeutic uses of CD137pos regulatory T cells
Swan et al. A requirement of protein geranylgeranylation for chemokine receptor signaling and Th17 cell function in an animal model of multiple sclerosis
Perez-Quintero et al. Immunotherapeutic implications of negative regulation by protein tyrosine phosphatases in T cells: the emerging cases of PTP1B and TCPTP
WO2023019128A1 (fr) Optimisation de l'état de différenciation de lymphocytes t avec des micro-arn
WO2023076523A1 (fr) Polypeptides adaptateurs chimériques
Harjunpaa Tumor immunity and autoimmunity following cancer immunotherapy
Leonard Ex vivo manipulation of CD8 T cells to improve adoptive cell therapy against cancer
Taefehshokr Regulation of Egr2 expression in T cells and Egr2/3 function in tumour infiltrating T cells
Lança Resposta dos linfócitos T ɣδ a tumoures: recrutamento, reconhecimento e funções
Lança Gamma-delta T cell responses to tumours: Recruitment, recognition and functions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11799553

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11799553

Country of ref document: EP

Kind code of ref document: A1